BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.
June 22, 2021
· 4 min read